Analytics4Life
 

blog

The Pulmonary Hypertension indication is the second FDA clearance for the CorVista System, amplifying its suite of diagnostic capabilities empowered by a proprietary algorithm derived from machine learning, to swiftly and accurately assess cardiovascular conditions at point-of-care The Pulmonary Hypertension (PH) Add-On will seamlessly...

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index=""][vc_column][vc_column_text]Washington DC—September 21, 2023—CorVista Health, Inc, a leading digital health company dedicated to improving cardiovascular disease diagnosis, is pleased to announce that it has been honored with the Editor’s Choice designation as the Top MedTech Startup for...

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index=""][vc_column][vc_column_text]Washington DC—October 25, 2022—CorVista Health, Inc, a digital health company dedicated to improving cardiovascular disease diagnosis, announces that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the CorVista System as a first...